FDA Grants Approval to Atezolizumab for Alveolar Soft Part Sarcoma
Evidence for efficacy is based on the results from the Study ML39345
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1533 results
Longer PFS in Patients with Advanced Melanoma Treated with TILs than among Those Who Received Ipilimumab
Findings from a randomised phase III study
One in Five of Older Patients with EBC Treated in a Prospective Cohort Received Low Chemotherapy Relative Dose Intensity and Had Inferior Survival
Findings from a prespecified secondary analysis of the HOPE study
Pembrolizumab Improves Survival in Patients from Asia with Previously Treated Advanced Hepatocellular Carcinoma
Findings from the KEYNOTE-394 study
FDA Approves Olutasidenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible IDH1 Mutation
It also approved the Abbott RealTime IDH1 Assay to select patients
Tucatinib in Combination with Trastuzumab and Capecitabine Provides Survival Benefits and Delays Development of New Brain Metastases in Patients with HER2-Positive MBC
Findings from an updated exploratory analysis of the HER2CLIMB study
Two-Step Approach Might Be An Alternative to Standard Three-Step Approach of the WHO Analgesic Ladder for Cancer Pain Management
Findings from an international randomised parallel group study
Utility of Prospective ctDNA Surveillance in Early TNBC and the Activity of Pembrolizumab in Patients with ctDNA Detected
Findings from c-TRAK TN study
Withdrawal of the Application to Change the EMA Marketing Authorisation for Pralsetinib
Application for extension of therapeutic indications concerned the use to treat patients from 12 years of age who have RET-mutated medullary thyroid cancer or RET fusion-positive thyroid cancer
FDA Approves Brentuximab Vedotin in Combination with Chemotherapy for Paediatric Patients with Classical Hodgkin Lymphoma
This is the first paediatric approval for brentuximab vedotin
Withdrawal of Application for the EMA Marketing Authorisation of Infigratinib
It was intended for previously treated adults with advanced cholangiocarcinoma
Daratumumab Plus Bortezomib and Dexamethasone Regimen Significantly Prolongs OS in Patients with Relapsed or Refractory Multiple Myeloma
Long-term overall survival results from the CASTOR study